Keywords
How to Cite
Abstract
Objective:
To compare the glycemic control outcomes of dapagliflozin plus metformin with sitagliptin plus metformin for the treatment of type 2 diabetes (T2D).
Methods:
This randomized clinical trial including 170 patients of T2D was conducted in department of medicine, CMH hospital from October-2023 to January-2025. Each patient was administered Metformin at a dosage of 500 mg taken twice daily. Patients in Group A were additionally treated with dapagliflozin at a daily dose of 10 mg, while those in Group B received sitagliptin at a dose of 100 mg, both in conjunction with Metformin. The follow-up period was 12 weeks.
Results:
Group A had an average age of 51.9 years (±8.5), whereas Group B was slightly older, with a mean age of 52.6 years (±7.8). Group A comprised 57.3% males, while Group B had 53.3% males. After 12 weeks, Group A's FBS improved to 118.6 ± 16.5 mg/dL, significantly lower than Group B's 142.8 ± 23.9 mg/dL (p < 0.0001). For HbA1c levels, Group A's baseline was 9.1 ± 1.4%, versus Group B's 8.9 ± 1.6% (p = 0.41). After 12 weeks, Group A showed a significant improvement in HbA1c, with a decrease to 7.1 ± 0.9%, while Group B's levels remained at 7.9 ± 1.2% (p < 0.0001).
Conclusion:
Combination of dapagliflozin plus metformin is more effective than the combination of sitagliptin plus metformin for treating T2D patients. We found a more significant decrease in FBS and HbA1c levels in the dapagliflozin plus metformin group.